Evidence map›Paper›PMID 33066815›Full record

ArticleHuman genomics2020

Mild dyserythropoiesis and β-like globin gene expression imbalance due to the loss of histone chaperone ASF1B.

Petros Papadopoulos, Athanassia Kafasi, Iris M De Cuyper, Vilma Barroca, Daniel Lewandowski, Zahra Kadri, Martijn Veldthuis, Jeffrey Berghuis, Nynke Gillemans, Celina María Benavente Cuesta and 6 more

Open access · goldAbstract read
In one paragraph

Article in Human genomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 5 countries.

Petros PapadopoulosDepartment of Cell Biology, Erasmus MC, Rotterdam, The Netherlands. petros.papadopoulos@salud.madrid.org.ORCID 0000-0002-8342-329X
Athanassia KafasiDepartment of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, AMC, UvA, Amsterdam, The Netherlands.
Iris M De CuyperDepartment of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, AMC, UvA, Amsterdam, The Netherlands.
Vilma BarrocaUMR Stabilité Génétique Cellules Souches et Radiations, Université de Paris and Université de Paris-Saclay, CEA, 18 route du Panorama, 92260, Fontenay-aux-Roses, France.
Daniel LewandowskiUMR Stabilité Génétique Cellules Souches et Radiations, Université de Paris and Université de Paris-Saclay, CEA, 18 route du Panorama, 92260, Fontenay-aux-Roses, France.
Zahra KadriDivision of Innovative Therapies, UMR1184, Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France.
Martijn VeldthuisLaboratory of Red Blood Cell Diagnostics, Sanquin Diagnostics, Amsterdam, The Netherlands.
Jeffrey BerghuisLaboratory of Red Blood Cell Diagnostics, Sanquin Diagnostics, Amsterdam, The Netherlands.
Nynke GillemansDepartment of Cell Biology, Erasmus MC, Rotterdam, The Netherlands.
Celina María Benavente CuestaDepartment of Hematology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.
Frank G GrosveldDepartment of Cell Biology, Erasmus MC, Rotterdam, The Netherlands.
Rob van ZwietenDepartment of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, AMC, UvA, Amsterdam, The Netherlands.
Sjaak PhilipsenDepartment of Cell Biology, Erasmus MC, Rotterdam, The Netherlands.
Muriel VernetUMR Stabilité Génétique Cellules Souches et Radiations, Université de Paris and Université de Paris-Saclay, CEA, 18 route du Panorama, 92260, Fontenay-aux-Roses, France.
Laura GutiérrezDepartment of Cell Biology, Erasmus MC, Rotterdam, The Netherlands.
George P PatrinosLaboratory of Pharmacogenomics and Individualized Therapy, Department of Pharmacy, University of Patras School of Health Sciences, Patras, Greece.
Erasmus MC · NLSanquin · NLInserm · FRInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESUniversité Paris Cité · FRUniversity of Patras · GR

Funding

Molecular basis of human gamma-globin gene activation.R01HL073455 · NHLBI · ERASMUS MEDICAL CENTER · PI GROSVELD, FRANKLIN G · 2003 to 2006
$859k
NHLBI NIH HHS R01 HL073455NIH HHS R01- HL073455)
6 · The paper itself

Abstract

The expression of the human β-like globin genes follows a well-orchestrated developmental pattern, undergoing two essential switches, the first one during the first weeks of gestation (ε to γ), and the second one during the perinatal period (γ to β). The γ- to β-globin gene switching mechanism includes suppression of fetal (γ-globin, HbF) and activation of adult (β-globin, HbA) globin gene transcription. In hereditary persistence of fetal hemoglobin (HPFH), the γ-globin suppression mechanism is impaired leaving these individuals with unusual elevated levels of fetal hemoglobin (HbF) in adulthood. Recently, the transcription factors KLF1 and BCL11A have been established as master regulators of the γ- to β-globin switch. Previously, a genomic variant in the KLF1 gene, identified by linkage analysis performed on twenty-seven members of a Maltese family, was found to be associated with HPFH. However, variation in the levels of HbF among family members, and those from other reported families carrying genetic variants in KLF1, suggests additional contributors to globin switching. ASF1B was downregulated in the family members with HPFH. Here, we investigate the role of ASF1B in γ- to β-globin switching and erythropoiesis in vivo. Mouse-human interspecies ASF1B protein identity is 91.6%. By means of knockdown functional assays in human primary erythroid cultures and analysis of the erythroid lineage in Asf1b knockout mice, we provide evidence that ASF1B is a novel contributor to steady-state erythroid differentiation, and while its loss affects the balance of globin expression, it has no major role in hemoglobin switching.

Indexed as

Animalsbeta-GlobinsCell Cycle ProteinsCell LineErythropoiesisgamma-GlobinsGene Expression RegulationHEK293 CellsHistone ChaperonesHumansKruppel-Like Transcription FactorsMice, KnockoutPolymorphism, Single NucleotideRepressor ProteinsRNA InterferenceASF1B protein, humanBCL11A protein, humanbeta-GlobinsCell Cycle Proteinserythroid Kruppel-like factorgamma-GlobinsHistone ChaperonesKruppel-Like Transcription FactorsRepressor ProteinsASF1BBCL11ADyserythropoiesisErythropoiesisGene expressionHemoglobin switchingHereditary persistence of fetal hemoglobin (HPFH)KLF1Thalassemia

Identifiers

PMID33066815
PMCPMC7566067
OpenAlexW3093278986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.